600161 Stock Overview
Beijing Tiantan Biological Products Co., Ltd. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 2/6 |
Beijing Tiantan Biological Products Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥21.26 |
| 52 Week High | CN¥27.60 |
| 52 Week Low | CN¥20.17 |
| Beta | 0.37 |
| 11 Month Change | -3.97% |
| 3 Month Change | -10.93% |
| 1 Year Change | -16.60% |
| 33 Year Change | 2.56% |
| 5 Year Change | 39.05% |
| Change since IPO | 182.74% |
Recent News & Updates
Recent updates
Shareholder Returns
| 600161 | CN Biotechs | CN Market | |
|---|---|---|---|
| 7D | -3.1% | -2.6% | -2.1% |
| 1Y | -16.6% | -20.9% | 2.8% |
Return vs Industry: 600161 matched the CN Biotechs industry which returned -17.3% over the past year.
Return vs Market: 600161 underperformed the CN Market which returned 5.4% over the past year.
Price Volatility
| 600161 volatility | |
|---|---|
| 600161 Average Weekly Movement | 4.7% |
| Biotechs Industry Average Movement | 8.9% |
| Market Average Movement | 8.3% |
| 10% most volatile stocks in CN Market | 12.6% |
| 10% least volatile stocks in CN Market | 5.6% |
Stable Share Price: 600161 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 600161's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1966 | 4,858 | Dao Xing Fu | www.tiantanbio.com |
Beijing Tiantan Biological Products Co., Ltd. engages in the research and development, manufacture, sale, and marketing of blood products in China and internationlly. Its products include human albumin; intravenous human immunoglobulin; rabies patient immunoglobulin; tetanus human immunoglobulin; hepatitis B human immunoglobulin; freeze-dried intravenous hepatitis B human immunoglobulin; histamine human immunoglobulin; human prothrombin complex; human coagulation factors VIII; human fibrinogen; recombinant human coagulation factor VIII for injection; and other blood products.
Beijing Tiantan Biological Products Co., Ltd. Fundamentals Summary
| 600161 fundamental statistics | |
|---|---|
| Market cap | CN¥42.04b |
| Earnings (TTM) | CN¥1.27b |
| Revenue (TTM) | CN¥5.23b |
33.0x
P/E Ratio8.0x
P/S RatioIs 600161 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 600161 income statement (TTM) | |
|---|---|
| Revenue | CN¥5.23b |
| Cost of Revenue | CN¥2.35b |
| Gross Profit | CN¥2.89b |
| Other Expenses | CN¥1.61b |
| Earnings | CN¥1.27b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.64 |
| Gross Margin | 55.17% |
| Net Profit Margin | 24.36% |
| Debt/Equity Ratio | 0% |
How did 600161 perform over the long term?
See historical performance and comparison